Similarly, the phase II Atezo-Brain trial evaluated atezolizumab with carboplatin/pemetrexed in EGFR- and ALK-negative nonsquamous NSCLC with untreated asymptomatic or symptomatically controlled BrMs [130]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.